Cell and Gene Therapy World Congress 2023
KEY INDUSTRY EXPERT SPEAKERS
- Doug Danison, Head of Commercial, Cell and Gene Therapy Unit, Bayer
- Eric Halioua, President & Chief Executive Officer, PDC*line Pharma
- Zhimei Du MD, VP of Process Sciences, Atara Biotherapeutics
- Wenliang Dong, Chief Operating Officer, ORCA Therapeutics
- Mohamed Oubihi, Founder and CEO, YAKUMED LIMITED
- Alberto Malerba, Lecturer in Gene Therapy, Royal Holloway University of London
- Mark Singh, Non-Clinical Manager, Cell and Gene Therapy Catapult
- Anthony Newcomb, Chief Operating Officer, VectorY
- Eugean Jiwanmall, Senior Research Analyst, Independence Blue Cross
- Cecilia Gotherstrom, Research Group leader, Associate Professor in Stem Cell Science, Karolinska Institute
- Nick Forsyth, Faculty Dean of Research, Keele University
- Vanessa Wellington, Research Scientist, University of Nottingham
- Stephen Judd, Process SME – Biologics / Cell & Gene Therapy, DPS Group
- Dr. Anand Srivastava, Chairman and Co-founder, Global Institute of Stem Cell Therapy and Research
- Amir Hefni, Global Head, Cell & Gene Therapy, Novartis
- Stefanos Theoharis, Independent Expert
- Alejandro Fernandez-Martell, former Principal Bioprocess Engineer, Achilles Therapeutics
- Stuart M Curbishley, Chief Manufacturing and Chief Development Officer, adthera bio
- Elsa Abranches, Sr Director,Head of Cell Therapy Bioprocess Development and Manufacturing, Astrazeneca*
- Ben Doak, Head of Innovative Treatments, NHS England.
- Mark Fowler, Global Head of Procurement, Autolus
- Francois Hallac, Research Associate, King's College London
- Julia Djonova, Head, Advanced Therapy Medicinal Products, Swissmedic
- Thomas Muller, Head Of Directorate General, Federal Ministry of Health Germany
- Manal Morsy, EVP, Head of Global Regulatory Affairs, Athersys, Inc
- Yue (Dina) Du, Senior Scientist, Gene Therapy R&D, AstraZeneca
- Reagan Jarvis, Chief Executive Officer and Co-founder, Anocca
- Matthias Bozza, Director, Vector BioPharma
- Chris Williams, SVP Corporate Development, Autolus Ltd.
- Dr Lilian Hook, Director Cell, Apheresis & Gene Therapies, NHS Blood and Transplant
- Dr. Thomas Schochat, Clinical Assessor, Division Advanced Therapy Products, Swissmedic
- Daniel Gibson, Director of Cell and Gene, Anthony Nolan
- Vera Citro, P4FIT Early Stage Researcher, Keele University
Dr Chris Williams
SVP Corporate Development
REAGAN JARVIS
CEO and Co-founder
MANAL MORSY
Executive Vice President, Head of Global Regulatory Affairs
Dr. Thomas Schochat
Clinical Assessor, Division Advanced Therapy Products
STUART M CURBISHLEY
Chief Manufacturing and Chief Development Officer
THOMAS MUELLER
Head of Directorate General “Drugs, Medical Devices, Biotechnology”
Federal Ministry of Health, Germany
THOMAS MUELLER
Head of Directorate General “Drugs, Medical Devices, Biotechnology”
MATTHIAS BOZZA
Director
Eric Halioua
President & Chief Executive Officer
Stephen Judd
Process SME – Biologics / Cell & Gene Therapy
Amir Hefni
Global Head for Cell & Gene Therapy
Daniel Gibson
Director of Cell and Gene
Vera Citro
P4FIT Early Stage Researcher
Stefanos Theoharis
Senior Executive
Dr. Anand Srivastava
Chairman and Co-founder
BEN DOAK
Head of Innovative Treatments
CECILIA GÖTHERSTRÖM
Research Group leader, Associate Professor in Stem Cell Science
Karolinska Institutet
CECILIA GÖTHERSTRÖM
Research Group leader, Associate Professor in Stem Cell Science
ALBERTO MALERBA
Lecturer in Gene Therapy
JULIA DJONOVA
Head, Advanced Therapy Medicinal Products
FRANCOIS HALLAC
Research Associate
DR LILIAN HOOK
Director Cell, Apheresis & Gene Therapies